Skip to main content Back to Top
Advertisement

5/28/2019

Furosemide Tablets

Products Affected - Description

    • Furosemide oral tablet, Hikma, 20 mg, bottle, 100 count, NDC 00054-4297-25
    • Furosemide oral tablet, Hikma, 20 mg, bottle, 1000 count, NDC 00054-4297-31
    • Furosemide oral tablet, Hikma, 20 mg, unit-dose blister pack, 100 count, NDC 00054-8297-25
    • Furosemide oral tablet, Hikma, 40 mg, bottle, 100 count, NDC 00054-4299-25
    • Furosemide oral tablet, Hikma, 40 mg, bottle, 1000 count, NDC 00054-4299-31
    • Furosemide oral tablet, Hikma, 40 mg, unit-dose blister pack, 100 count, NDC 00054-8299-25
    • Furosemide oral tablet, Hikma, 80 mg, bottle, 100 count, NDC 00054-4301-25
    • Furosemide oral tablet, Hikma, 80 mg, unit-dose blister pack, 100 count, NDC 00054-8301-25

Reason for the Shortage

    • Major discontinued furosemide tablets in early-2018.
    • Mylan refuses to provide availability information.
    • Hikma states the shortage is due to manufacturing delays.
    • Sandoz discontinued furosemide tablets in late-August 2017.
    • Teva discontinued furosemide tablets in June 2018

Available Products

    • Lasix oral tablet, Validus Pharmaceuticals, 20 mg, bottle, 100 count, NDC 30698-0067-01
    • Lasix oral tablet, Validus Pharmaceuticals, 40 mg, bottle, 50 count, NDC 30698-0066-05
    • Lasix oral tablet, Validus Pharmaceuticals, 40 mg, bottle, 100 count, NDC 30698-0060-01
    • Furosemide oral tablet, Hikma, 80 mg, bottle, 500 count, NDC 00054-4301-29

Estimated Resupply Dates

    • Hikma has furosemide 20 mg tablets in 100 count unit dose packs, 20 mg tablets in 100 count and 1,000 count bottles, 40 mg tablets in 100 count unit dose packs, 40 mg tablets in 100 count and 1,000 count bottles, 80 mg tablets in 100 count bottles, and 80 mg tablets in 100 count unit dose packs on allocation.

Updated

Updated May 28, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 8, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins